Trametes acid and sorafenib combined drug and application thereof in preparation of antitumor drugs

The invention provides application of a trametes acid and sorafenib combined drug in-vivo and in-vitro combined drug in cancer resistance, provides a method for ensuring the treatment effect of sorafenib on various tumors and overcoming sorafenib drug resistance, and provides a treatment scheme for treating sorafenib drug resistance and improving the curative effect of patients with advanced cancers. The trametes acid and sorafenib combined drug has the advantages that 1, TAB and sorafenib are combined, so that a synergistic tumor inhibition effect is achieved, and the proliferation inhibition of various tumor cells of digestive and respiratory systems can be enhanced in vivo and in vitro; 2, TAB and sorafenib are combined, so that the sorafenib drug resistance can be overcome, and the trametes acid and sorafenib combined drug is used for sorafenib drug-resistant tumor treatment; and 3, TAB and sorafenib are combined, so that the sensitivity to sorafenib can be enhanced by inhibiting the activation of a PI3K/